RxDoctor Payments Data

Guillermo Guardia Gonzales, MD

Endocrinology, Diabetes & Metabolism · Toledo, OHNPI 1902866387

Payments from drug & device makers

$724in general payments, 2019–2025

Across 15 payments — averaging $48.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$463
  • Dexcom, Inc.$127
  • Amgen$36
  • Abbott$25
  • Medtronic$18
  • Antares Pharma, Inc.$16
  • plus $38 from 3 others

What the payments were for

  • Travel & lodging$46364%
  • Food & beverage$26136%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$724 in reported general payments places this provider in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$131,859
Medicare patients
665
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide454$537,400
OzempicSemaglutide316$438,739
JardianceEmpagliflozin153$173,973
TrulicityDulaglutide108$169,056
Tresiba Flextouch U-100Insulin Degludec115$100,047
Tresiba Flextouch U-200Insulin Degludec60$97,744
JanuviaSitagliptin Phosphate86$92,280
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog111$70,059
Humulin R U-500 KwikpenInsulin Regular, Human28$67,109
Lantus SolostarInsulin Glargine,hum.Rec.Anlog320$60,245
FarxigaDapagliflozin Propanediol37$46,523
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog26$40,301
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$38,249
Humalog Kwikpen U-100Insulin Lispro100$36,689
Fiasp FlextouchInsulin Aspart (Niacinamide)47$35,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$13$13,352207 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →